News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$MNKD MannKind CEO Michael Castagna commercializing new generation of inhalable treatments MNKD
https://www.fierceceo.com/growth-innovation/mannkind-ceo-michael-castagna-commercializing-new-generation-inhalable-treatments
$WPWR Well Power Inc. (WPWR) – Focused on Monetizing Huge Untapped Energy Source WPWR
Houston-based energy technologies company Well Power is focused on the application of a valuable new energy technology for the U.S. oil industry. The technology, called Micro Refinery Units (MRU), was developed by ME Resource Corp., a publicly listed Canadian resource company targeting the acquisition, exploration, and development of oil and gas resource properties in Canada and Internationally. ME Resource has granted Well Power the licensing rights to Texas, along with the first right of refusal for the other U.S. states, to this new technology.
The MRU technology is all about the processing of waste natural gas, a byproduct of oil production that usually ends up being wastefully vented, flared, or stranded. Global gas flaring, the burning off of this excess gas, represents not only a huge energy waste, but also an environmental issue. Gas flaring amounts to roughly 150 billion cubic meters each year, resulting in 400 million metric tons of carbon dioxide equivalent greenhouse gas emissions. To get an idea of the significance, and potential, of gas flaring, consider the fact that global gas flaring represents approximately 30% of the total annual gas requirements of the entire European Union.
Well Power’s licensed MRU technology provides a unique way of taking this waste natural gas and converting it into Green FuelTM and clean power, with a solution that is mobile, high-yield, and economical to deploy. The MRU system combines proven commercial technologies together with a proprietary micro-reactor for hydrocarbon processing and catalytic reactions.
Over and above its obvious value in converting a pollution source into clean power and engineered fuels, including no-sulphur diesel and diluents, the MRU solution is flexible, scalable, modular, efficient, and easily custom configured. The proprietary technology is mobile and can be deployed with minimum capital expenditure.
Well Power’s license allows the company to provide the technology with full-service engineering, design, construction, modular fabrication, maintenance, and construction management services to clients in the upstream areas of exploration and production. Well Power can also provide consulting services, process assessments, facility appraisals, feasibility studies, technology evaluations, project finance structuring and support, and multi-client subscription services.
For additional information on the technology, see a recent write-up in Oil & Gas Network, at http://issuu.com/oilgasnetwork/docs/ogn_june_2015l
$PMCB Ascites Market by treatment, diagnosis (ultrasound, CT scan) and end user - Forecast to 2022 PMCB
http://www.einnews.com/pr_news/359099074/ascites-market-by-treatment-diagnosis-ultrasound-ct-scan-and-end-user-forecast-to-2022
$PMCB Dr. Crabtree’s professional career was his tenure as Director of Project Planning and Management (Oncology and Immunology) at Bristol-Myers Squibb (“BMS”) from 1990 to 1997. While at BMS, Dr. Crabtree established and directed a department that monitored and coordinated the development of all oncologic and immunologic drugs from initial discovery through regulatory approval within BMS and served as Project Manager for the development of the major anticancer agent, Taxol®, the “number one” drug under development at BMS at that time. Taxol® ultimately became a multi-billion dollar drug for BMS and is still widely used to treat a variety of cancers.
$PMCB GENE THERAPY FOR TYPE 1 DIABETES
Ann M. Simpson
Centre for Health Technologies
http://www.uts.edu.au/sites/default/files/sci-infectious-diseases-presentation-ann-simpson.pdf
http://pharmacyte.com/diabetes/
Go $PMCB
$PMCB Functional cure diabetes should finally become reality
A-Dornbirn | The International Diabetes consortium headed by Dr. Eva Maria Brandtner from residents in Vorarlberg VIVIT Institute has set itself the goal of being able to heal Type 1 diabetes in the future. This will be achieved by transplantation of encapsulated cells insulinprodzierender.
Type 1 diabetes is an autoimmune disease, (also called islet cells) which destroy the beta cells in the pancreas (pancreatic) leads, which are responsible for the production of insulin. The disease usually occurs in childhood, and the patients are dependent for the rest of their lives meshed blood glucose testing and insulin injections. Despite these physically and mentally stressful duration therapy often occur in both acute and long-term complications; these are z.T. severe.
A beta cell transplantation is already feasible today and is the only way, the physiological blood sugar regulation in type 1 diabetes produce patient. In practice, however, they very rarely be used: Firstly, because of the extreme shortage of donor organs and, secondly, because of the devastating effects of immunosuppression associated with organ transplantation. The latter can, however, be avoided by encapsulating the beta cells prior to implantation and so mechanically protects against immune attack.
Efforts to implement this concept in a clinical product were far overshadowed by lack of longevity of the transplanted beta cells. The implanted cells usually died from the effects of toxic mediators. The present project aims at the introduction of a new, alternative insulin-producing cell type. These are genetically modified liver cells, which are much more resistant to said messengers as pancreatic islet cells, since the liver is our detoxifying organ and its cells are adapted to adverse conditions. Furthermore, to increase the introduction of a Zelllverkapselungsmaterials with outstanding biocompatibility the life of grafts significantly. The combination of these two innovations should lead to a significant improvement in the long-term functionality of transplanted insulin-producing cells. Currently, tests are still carried out on animals. First human clinical trials are expected in three to five years.
At present project ten institutions in Europe, the USA, Asia and Australia are now involved who have come together at the initiative of the American company PharmaCyte Biotech for so-called International Diabetes Consortium (http://www.pharmacyte.com/intldiabetesconsortium/). Dr. Eva Maria (Lilli) Brandtner, Associate of VIVIT Institute in Vorarlberg, is leading the project in their role as "Director of Diabetes Program Development" for PharmaCyte Biotech (http://www.pharmacyte.com/management/). Previously Dr. Brandtner spent five years in Asia biotech center Singapore as Chief Scientist at the Zellverkapselungs company Austrianova (http://www.austrianova.com) who is also a member of Diabetes Consortium today. Dr. Brandtners return to Austria was supported by the 7th Framework Programme of the European Commission (http://www.cordis.europa.eu/project/rcn/110678_en.html). In autumn 2015, the International Diabetes Consortium could forward to Dr. Hans Peter Hammes, Professor of Internal Medicine and Endocrinology, Faculty of Clinical Medicine Mannheim, University of Heidelberg and Section Head of Endocrinology welcome. As a globally recognized diabetes expert is Prof. Dr. Hans-Peter Hammes the consortium with the ultimate experience both as a physician and as a scientist and active support.
$PMCB Functional cure diabetes should finally become reality
A-Dornbirn | The International Diabetes consortium headed by Dr. Eva Maria Brandtner from residents in Vorarlberg VIVIT Institute has set itself the goal of being able to heal Type 1 diabetes in the future. This will be achieved by transplantation of encapsulated cells insulinprodzierender.
Type 1 diabetes is an autoimmune disease, (also called islet cells) which destroy the beta cells in the pancreas (pancreatic) leads, which are responsible for the production of insulin. The disease usually occurs in childhood, and the patients are dependent for the rest of their lives meshed blood glucose testing and insulin injections. Despite these physically and mentally stressful duration therapy often occur in both acute and long-term complications; these are z.T. severe.
A beta cell transplantation is already feasible today and is the only way, the physiological blood sugar regulation in type 1 diabetes produce patient. In practice, however, they very rarely be used: Firstly, because of the extreme shortage of donor organs and, secondly, because of the devastating effects of immunosuppression associated with organ transplantation. The latter can, however, be avoided by encapsulating the beta cells prior to implantation and so mechanically protects against immune attack.
Efforts to implement this concept in a clinical product were far overshadowed by lack of longevity of the transplanted beta cells. The implanted cells usually died from the effects of toxic mediators. The present project aims at the introduction of a new, alternative insulin-producing cell type. These are genetically modified liver cells, which are much more resistant to said messengers as pancreatic islet cells, since the liver is our detoxifying organ and its cells are adapted to adverse conditions. Furthermore, to increase the introduction of a Zelllverkapselungsmaterials with outstanding biocompatibility the life of grafts significantly. The combination of these two innovations should lead to a significant improvement in the long-term functionality of transplanted insulin-producing cells. Currently, tests are still carried out on animals. First human clinical trials are expected in three to five years.
At present project ten institutions in Europe, the USA, Asia and Australia are now involved who have come together at the initiative of the American company PharmaCyte Biotech for so-called International Diabetes Consortium (http://www.pharmacyte.com/intldiabetesconsortium/). Dr. Eva Maria (Lilli) Brandtner, Associate of VIVIT Institute in Vorarlberg, is leading the project in their role as "Director of Diabetes Program Development" for PharmaCyte Biotech (http://www.pharmacyte.com/management/). Previously Dr. Brandtner spent five years in Asia biotech center Singapore as Chief Scientist at the Zellverkapselungs company Austrianova (http://www.austrianova.com) who is also a member of Diabetes Consortium today. Dr. Brandtners return to Austria was supported by the 7th Framework Programme of the European Commission (http://www.cordis.europa.eu/project/rcn/110678_en.html). In autumn 2015, the International Diabetes Consortium could forward to Dr. Hans Peter Hammes, Professor of Internal Medicine and Endocrinology, Faculty of Clinical Medicine Mannheim, University of Heidelberg and Section Head of Endocrinology welcome. As a globally recognized diabetes expert is Prof. Dr. Hans-Peter Hammes the consortium with the ultimate experience both as a physician and as a scientist and active support.
$PMCB A patent’s just been granted for what could be a functional ‘cure’ for type 1 diabetes
We’re so ready.
JACINTA BOWLER 26 MAY 2016
Type 1 diabetes isn’t an easy disease to put an end to; not only do scientists have to fix the complete lack of insulin being produced by the patient’s own pancreas, but the cells they try to send in to help keep getting destroyed by the immune system. It’s a medical catch-22.
But a US patent has just been approved for what could be the first functional cure for the condition – by combining insulin-delivering cells with technology that allows them to hide from the immune system for years at a time.
The cells are called ‘Melligen cells’, and they can produce, store, and release insulin in response to human blood sugar levels.
University of Technology Sydney (UTS) scientists have been genetically engineering these Melligen cells for years so they can release insulin in order to regulate human blood sugar levels – just like the beta cells that are destroyed by type 1 diabetes are supposed to.
And last year, the team published a paper showing they could reverse type 1 diabetes in mice.
That was great, but those mice were immunocompromised, which meant they didn’t have an immune response. In the human body, the cells would still be attacked on entry. And that’s where this new collaboration comes in.
The UTS scientists have now joined up with US clinical stage biotechnology company PharmaCyte Biotech, who have developed a product called Cell-in-a-Box that can, in theory, encapsulate the Melligen cells and hide them from the immune system. They’ve just patented the combination.
"My team and I are extremely pleased that the US patent for the Melligen cells has been granted," says lead researcher at UTS, Ann Simpson. "This takes us a step closer to releasing diabetics from the need to inject insulin daily and, more importantly, protecting them from the debilitating complications of the disease such as blindness, kidney failure and cardiovascular problems."
The aim of Cell-in-a-Box is to completely remove the immune system issue by encapsulating the Melligen cells in an immune system friendly coating, allowing them to chill out in the pancreas without being attacked.
The special cellulose structure that makes up the Cell-in-a-Box allows molecules to move in and out, letting the Melligen cells know when blood sugar is low, and producing and releasing insulin when required - all without the immune system realising it’s there.
"This is a culmination of many years’ work by our group and we look forward to working with PharmaCyte's Diabetes Consortium to utilise the Cell-in–a-Box technology to encapsulate the cells for preclinical trials aimed at curing diabetes," says Simpson.
"We anticipate that the capsule technology will protect the Melligen cells from the body's immune response that normally destroys foreign tissue, allowing the Melligen cells to be transplanted into humans."
The Cell-in-a-Box technology is able to stay in the body for at least two years without damage or damaging tissue nearby, meaning it could be a long-term solution for type 1 diabetes sufferers. We are exceptionally excited to see what human trials show, as this could bring us closer than ever to a functional cure for a pretty dangerous disease.
To be clear, although there are peer-reviewed studies for both of these technologies, there have not been any on the combination of Melligen cells and Cell-in-a-Box together, and how they will work together to fight type 1 diabetes. But now that the patent has been granted, the researchers will be moving into trials.
"If we are successful in this effort, it will bring to fruition the many years of research that have been conducted by Professor Simpson and her colleagues at UTS in developing these remarkable cells,” said PharmaCyte’s CEO, Kenneth Waggoner.
"For the millions of people worldwide who suffer from a disease of epidemic proportions, our treatment could relieve them of the onerous daily requirements for insulin administration and dietary restrictions and offer a life free from the very serious and even life-threatening complications associated with diabetes."
UTS Science is a sponsor of ScienceAlert. Find out more about their research.
http://www.sciencealert.com/a-patent-s-just-been-granted-for-what-could-be-a-functional-cure-for-type-1-diabetes
|
Followers
|
12
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
96
|
|
Created
|
06/07/16
|
Type
|
Free
|
| Moderators | |||
